Microbial Genomics: Innovative Targets and Mechanisms

Multidrug resistance (MDR) has become an increasing threat to global health because bacteria can develop resistance to antibiotics over time. Scientists worldwide are searching for new approaches that go beyond traditional antibiotic discovery and development pipelines. Advances in genomics, however, opened up an unexplored therapeutic opportunity for the discovery of new antibacterial agents. Genomic approaches have been used to discover several novel antibiotics that target critical processes for bacterial growth and survival, including histidine kinases (HKs), LpxC, FabI, peptide deformylase (PDF), and aminoacyl-tRNA synthetases (AaRS). In this review, we will discuss the use of microbial genomics in the search for innovative and promising drug targets as well as the mechanisms of action for novel antimicrobial agents. We will also discuss future directions on how the utilization of the microbial genomics approach could improve the odds of antibiotic development having a more successful outcome.

[1]  Xuefu You,et al.  Recent Advances in Histidine Kinase-Targeted Antimicrobial Agents , 2022, Frontiers in Chemistry.

[2]  Christopher M Thomas,et al.  High quality genome annotation and expression visualisation of a mupirocin-producing bacterium , 2022, PloS one.

[3]  C. Rock,et al.  A genome-wide atlas of antibiotic susceptibility targets and pathways to tolerance , 2022, Nature Communications.

[4]  J. Rolain,et al.  Application and Challenge of 3rd Generation Sequencing for Clinical Bacterial Studies , 2022, International journal of molecular sciences.

[5]  N. Nandi,et al.  Dynamics of the Catalytic Active Site of Isoleucyl tRNA Synthetase from Staphylococcus aureus bound with Adenylate and Mupirocin. , 2022, The journal of physical chemistry. B.

[6]  Ashutosh Kumar Singh,et al.  Analysis of Biosynthetic Gene Clusters, Secretory, and Antimicrobial Peptides Reveals Environmental Suitability of Exiguobacterium profundum PHM11 , 2022, Frontiers in Microbiology.

[7]  Adrian Mejia-Santana,et al.  Union Is Strength: Target-Based and Whole-Cell High-Throughput Screens in Antibacterial Discovery , 2021, Journal of bacteriology.

[8]  Agustín M. Pardo,et al.  From Genome to Drugs: New Approaches in Antimicrobial Discovery , 2021, Frontiers in Pharmacology.

[9]  V. Sintchenko,et al.  Microbial Genomics as a Catalyst for Targeted Antivirulence Therapeutics , 2021, Frontiers in Medicine.

[10]  K. Yusoff,et al.  Membrane Disruption Properties of Essential Oils—A Double-Edged Sword? , 2021 .

[11]  R. Brenk,et al.  Riboswitches as Drug Targets for Antibiotics , 2021, Antibiotics.

[12]  K. Lai,et al.  The Missing Piece: Recent Approaches Investigating the Antimicrobial Mode of Action of Essential Oils , 2021, Evolutionary bioinformatics online.

[13]  Jonathan M. Monk,et al.  Pangenome Analytics Reveal Two-Component Systems as Conserved Targets in ESKAPEE Pathogens , 2020, mSystems.

[14]  Naveen Sorout,et al.  The Integration of Genome Mining, Comparative Genomics, and Functional Genetics for Biosynthetic Gene Cluster Identification , 2020, Frontiers in Genetics.

[15]  Bernhard Y. Renard,et al.  Predicting bacterial virulence factors - evaluation of machine learning and negative data strategies , 2020, Briefings Bioinform..

[16]  Miguel A. Matilla,et al.  Mining for novel antibiotics in the age of antimicrobial resistance , 2020, Microbial biotechnology.

[17]  S. Chopra,et al.  FabI (enoyl acyl carrier protein reductase) - A potential broad spectrum therapeutic target and its inhibitors. , 2020, European journal of medicinal chemistry.

[18]  K. Chakraborty,et al.  Moving away from traditional antibiotic treatment: can macrocyclic lactones from marine macroalga-associated heterotroph be the alternatives? , 2020, Applied Microbiology and Biotechnology.

[19]  W. Low,et al.  Transcriptomic analysis of multi-drug resistant Escherichia coli K-12 strain in response to Lavandula angustifolia essential oil , 2020, 3 Biotech.

[20]  L. Weyrich,et al.  Palaeomicrobiology: Application of Ancient DNA Sequencing to Better Understand Bacterial Genome Evolution and Adaptation , 2020, Frontiers in Ecology and Evolution.

[21]  Qipeng Yuan,et al.  Biosynthesis of aromatic polyketides in microorganisms using type II polyketide synthases , 2020, Microbial Cell Factories.

[22]  R. Teta,et al.  Identification of the Biosynthetic Gene Cluster of Thermoactinoamides and Discovery of New Congeners by Integrated Genome Mining and MS-Based Molecular Networking , 2020, Frontiers in Chemistry.

[23]  Hosein Mohimani,et al.  Linking genomics and metabolomics to chart specialized metabolic diversity. , 2020, Chemical Society reviews.

[24]  E. Mazurkiewicz,et al.  Prevention of biofilm formation by quorum quenching , 2020, Applied Microbiology and Biotechnology.

[25]  I. Hanski.  Metapopulations , 2019, Encyclopedia of Theoretical Ecology.

[26]  Christiane Chbib.  Impact of the structure-activity relationship of AHL analogues on quorum sensing in Gram-negative bacteria. , 2019, Bioorganic & medicinal chemistry.

[27]  G. Soberón-Chávez,et al.  The third quorum-sensing system of Pseudomonas aeruginosa: Pseudomonas quinolone signal and the enigmatic PqsE protein. , 2019, Journal of medical microbiology.

[28]  C. MacNair,et al.  Creative targeting of the Gram‐negative outer membrane in antibiotic discovery , 2019, Annals of the New York Academy of Sciences.

[29]  Fabio Polticelli,et al.  In silico Selection and Experimental Validation of FDA-Approved Drugs as Anti-quorum Sensing Agents , 2019, Front. Microbiol..

[30]  F. Cohen,et al.  Potent LpxC Inhibitors with In Vitro Activity against Multidrug-Resistant Pseudomonas aeruginosa , 2019, Antimicrobial Agents and Chemotherapy.

[31]  Robert Penchovsky,et al.  Riboswitch distribution, structure, and function in bacteria. , 2019, Gene.

[32]  S. Lee,et al.  antiSMASH 5.0: updates to the secondary metabolite genome mining pipeline , 2019, Nucleic Acids Res..

[33]  Suzana M. Ribeiro,et al.  Recent Advances in Anti-virulence Therapeutic Strategies With a Focus on Dismantling Bacterial Membrane Microdomains, Toxin Neutralization, Quorum-Sensing Interference and Biofilm Inhibition , 2019, Front. Cell. Infect. Microbiol..

[34]  E. Kristiansson,et al.  Identification and reconstruction of novel antibiotic resistance genes from metagenomes , 2019, Microbiome.

[35]  B. Felden,et al.  Future antibacterial strategies: from basic concepts to clinical challenges. , 2019, The Journal of infectious diseases.

[36]  P. Visca,et al.  Activity and Impact on Resistance Development of Two Antivirulence Fluoropyrimidine Drugs in Pseudomonas aeruginosa , 2019, Front. Cell. Infect. Microbiol..

[37]  J. Mecsas,et al.  Promises and Challenges of the Type Three Secretion System Injectisome as an Antivirulence Target. , 2019, EcoSal Plus.

[38]  Karunakaran A Kalesh,et al.  The Quest for Novel Antimicrobial Compounds: Emerging Trends in Research, Development, and Technologies , 2019, Antibiotics.

[39]  C. Francklyn,et al.  Progress and challenges in aminoacyl-tRNA synthetase-based therapeutics , 2019, The Journal of Biological Chemistry.

[40]  Seth M. Cohen,et al.  Targeting Metalloenzymes for Therapeutic Intervention. , 2018, Chemical reviews.

[41]  V. Sintchenko,et al.  Genome-wide analysis of Streptococcus pneumoniae serogroup 19 in the decade after the introduction of pneumococcal conjugate vaccines in Australia , 2018, Scientific Reports.

[42]  C. Harwood,et al.  Secondary metabolite production and the safety of industrially important members of the Bacillus subtilis group , 2018, FEMS microbiology reviews.

[43]  R. Breaker.  Riboswitches and Translation Control. , 2018, Cold Spring Harbor perspectives in biology.

[44]  H. Yoshikawa,et al.  Essentiality and function of WalK/WalR two-component system: the past, present, and future of research* , 2018, Bioscience, biotechnology, and biochemistry.

[45]  A. Miyanaga.  Structure and function of polyketide biosynthetic enzymes: various strategies for production of structurally diverse polyketides , 2017, Bioscience, biotechnology, and biochemistry.

[46]  Mark M. Tanaka,et al.  Comparative genomics of Australian and international isolates of Salmonella Typhimurium: correlation of core genome evolution with CRISPR and prophage profiles , 2017, Scientific Reports.

[47]  F. Buckner,et al.  Development of Methionyl-tRNA Synthetase Inhibitors as Antibiotics for Gram-Positive Bacterial Infections , 2017, Antimicrobial Agents and Chemotherapy.

[48]  M. McConnell,et al.  Using bacterial genomes and essential genes for the development of new antibiotics , 2017, Biochemical pharmacology.

[49]  H. Jafri,et al.  New Strategies Targeting Virulence Factors of Staphylococcus aureus and Pseudomonas aeruginosa , 2017, Seminars in Respiratory and Critical Care Medicine.

[50]  Michael A. Skinnider,et al.  PRISM 3: expanded prediction of natural product chemical structures from microbial genomes , 2017, Nucleic Acids Res..

[51]  Kai Blin,et al.  antiSMASH 4.0—improvements in chemistry prediction and gene cluster boundary identification , 2017, Nucleic Acids Res..

[52]  Anders F. Andersson,et al.  Metapopulation theory identifies biogeographical patterns among core and satellite marine bacteria scaling from tens to thousands of kilometers , 2017, Environmental microbiology.

[53]  Y. Eguchi,et al.  Angucycline antibiotic waldiomycin recognizes common structural motif conserved in bacterial histidine kinases , 2016, The Journal of Antibiotics.

[54]  M. Seyedsayamdost,et al.  Antibiotic dialogues: induction of silent biosynthetic gene clusters by exogenous small molecules , 2017, FEMS microbiology reviews.

[55]  Meetu Gupta,et al.  Bacterial Virulence Factors: Secreted for Survival , 2017, Indian Journal of Microbiology.

[56]  Christopher P. Zschiedrich,et al.  The Rational Design, Synthesis, and Antimicrobial Properties of Thiophene Derivatives That Inhibit Bacterial Histidine Kinases. , 2016, Journal of medicinal chemistry.

[57]  Yuemao Shen,et al.  Licoflavonol is an inhibitor of the type three secretion system of Salmonella enterica serovar Typhimurium. , 2016, Biochemical and biophysical research communications.

[58]  A. Erwin.  Antibacterial Drug Discovery Targeting the Lipopolysaccharide Biosynthetic Enzyme LpxC. , 2016, Cold Spring Harbor perspectives in medicine.

[59]  R. Epand,et al.  Molecular mechanisms of membrane targeting antibiotics. , 2016, Biochimica et biophysica acta.

[60]  M. Gelb,et al.  5-Fluoroimidazo[4,5-b]pyridine Is a Privileged Fragment That Conveys Bioavailability to Potent Trypanosomal Methionyl-tRNA Synthetase Inhibitors , 2016, ACS infectious diseases.

[61]  J. Kim,et al.  Prospects of a new antistaphylococcal drug batumin revealed by molecular docking and analysis of the complete genome sequence of the batumin-producer Pseudomonas batumici UCM B-321. , 2016, International journal of antimicrobial agents.

[62]  Y. Eguchi,et al.  Study on in vivo effects of bacterial histidine kinase inhibitor, Waldiomycin, in Bacillus subtilis and Staphylococcus aureus. , 2015, The Journal of general and applied microbiology.

[63]  T. Hwa,et al.  Inflating bacterial cells by increased protein synthesis , 2015, Molecular systems biology.

[64]  N. Makridakis,et al.  Whole-genome sequencing targets drug-resistant bacterial infections , 2015, Human Genomics.

[65]  Mark Goulian,et al.  Signal transduction in histidine kinases: insights from new structures. , 2015, Structure.

[66]  A. Cambi,et al.  Editorial: Membrane domains as new drug targets , 2015, Front. Physiol..

[67]  J. Sumida,et al.  Inhibition and Reversal of Microbial Attachment by an Antibody with Parasteric Activity against the FimH Adhesin of Uropathogenic E. coli , 2015, PLoS pathogens.

[68]  A. Marina,et al.  Bacterial histidine kinases as novel antibacterial drug targets. , 2015, ACS chemical biology.

[69]  K. Lewis,et al.  A new antibiotic kills pathogens without detectable resistance , 2015, Nature.

[70]  J. Sangshetti,et al.  Peptide deformylase: a new target in antibacterial, antimalarial and anticancer drug discovery. , 2014, Current medicinal chemistry.

[71]  M. Achtman,et al.  Distinct Genealogies for Plasmids and Chromosome , 2014, PLoS genetics.

[72]  M. Kuhn,et al.  LpxC Inhibitors as New Antibacterial Agents and Tools for Studying Regulation of Lipid A Biosynthesis in Gram-Negative Pathogens , 2014, mBio.

[73]  O. Franco,et al.  Insights into novel antimicrobial compounds and antibiotic resistance genes from soil metagenomes , 2014, Front. Microbiol..

[74]  O. Franco,et al.  The use of versatile plant antimicrobial peptides in agribusiness and human health , 2014, Peptides.

[75]  Changji Zheng,et al.  Meleagrin, a New FabI Inhibitor from Penicillium chryosogenum with at Least One Additional Mode of Action , 2013, PloS one.

[76]  O. Franco,et al.  Purification, biochemical characterization and self-assembled structure of a fengycin-like antifungal peptide from Bacillus thuringiensis strain SM1 , 2013, Front. Microbiol..

[77]  E. Donkor.  Sequencing of Bacterial Genomes: Principles and Insights into Pathogenesis and Development of Antibiotics , 2013, Genes.

[78]  A. Karchmer,et al.  Is there a future for FabI inhibitors as antibacterial agents , 2013 .

[79]  Robert Penchovsky,et al.  Riboswitch-based antibacterial drug discovery using high-throughput screening methods , 2013, Expert opinion on drug discovery.

[80]  R. Breaker.  Riboswitches and the RNA world. , 2012, Cold Spring Harbor perspectives in biology.

[81]  L. Garcia,et al.  Quorum quenching quandary: resistance to antivirulence compounds , 2011, The ISME Journal.

[82]  Pengcheng Lv,et al.  Aminoacyl-tRNA synthetase inhibitors as potent antibacterials. , 2012, Current medicinal chemistry.

[83]  J. Walker,et al.  Mechanisms Decreasing In Vitro Susceptibility to the LpxC Inhibitor CHIR-090 in the Gram-Negative Pathogen Pseudomonas aeruginosa , 2011, Antimicrobial Agents and Chemotherapy.

[84]  D. Livermore.  Discovery research: the scientific challenge of finding new antibiotics. , 2011, The Journal of antimicrobial chemotherapy.

[85]  Y. Tor,et al.  Antibiotics that target protein synthesis , 2011, Wiley interdisciplinary reviews. RNA.

[86]  Wim G. J. Hol,et al.  Selective Inhibitors of Methionyl-tRNA Synthetase Have Potent Activity against Trypanosoma brucei Infection in Mice , 2011, Antimicrobial Agents and Chemotherapy.

[87]  V. Sperandio,et al.  Anti-virulence strategies to combat bacteria-mediated disease , 2010, Nature Reviews Drug Discovery.

[88]  Igor B. Zhulin,et al.  The MiST2 database: a comprehensive genomics resource on microbial signal transduction , 2009, Nucleic Acids Res..

[89]  A. West,et al.  Histidine Kinases in Two-Component Signaling Pathways , 2010 .

[90]  A. Delcour,et al.  Outer membrane permeability and antibiotic resistance. , 2009, Biochimica et biophysica acta.

[91]  A. Cross.  What is a virulence factor? , 2008, Critical care.

[92]  Pei Zhou,et al.  Mechanism and inhibition of LpxC: an essential zinc-dependent deacetylase of bacterial lipid A synthesis. , 2008, Current pharmaceutical biotechnology.

[93]  A. Coates,et al.  Novel approaches to developing new antibiotics for bacterial infections , 2007, British journal of pharmacology.

[94]  Pei Zhou,et al.  Structure of the deacetylase LpxC bound to the antibiotic CHIR-090: Time-dependent inhibition and specificity in ligand binding , 2007, Proceedings of the National Academy of Sciences.

[95]  C. Raetz,et al.  Lipid A modification systems in gram-negative bacteria. , 2007, Annual review of biochemistry.

[96]  R. Rappuoli,et al.  The pan-genome: towards a knowledge-based discovery of novel targets for vaccines and antibacterials. , 2007, Drug discovery today.

[97]  Pei Zhou,et al.  Inhibition of lipid A biosynthesis as the primary mechanism of CHIR-090 antibiotic activity in Escherichia coli. , 2007, Biochemistry.

[98]  M. Simon,et al.  Two-component signaling systems , 2007 .

[99]  M. Inouye,et al.  The design and development of Tar-EnvZ chimeric receptors. , 2007, Methods in enzymology.

[100]  M. Pirrung,et al.  Molecular Validation of LpxC as an Antibacterial Drug Target in Pseudomonas aeruginosa , 2006, Antimicrobial Agents and Chemotherapy.

[101]  R. Monaghan,et al.  Antibacterial drug discovery--then, now and the genomics future. , 2006, Biochemical pharmacology.

[102]  J. Rudolph,et al.  A slow, tight-binding inhibitor of the zinc-dependent deacetylase LpxC of lipid A biosynthesis with antibiotic activity comparable to ciprofloxacin. , 2005, Biochemistry.

[103]  C. Fraser-Liggett,et al.  Insights on biology and evolution from microbial genome sequencing. , 2005, Genome research.

[104]  D. Chen,et al.  Bacterial Peptide deformylase inhibitors: a new class of antibacterial agents. , 2005, Current medicinal chemistry.

[105]  C. Glass,et al.  A comprehensive classification system for lipids. , 2005, Journal of lipid research.

[106]  D. Payne,et al.  Finding the gems using genomic discovery: antibacterial drug discovery strategies – the successes and the challenges , 2004 .

[107]  S. Amyes,et al.  Microbiology and drug resistance mechanisms of fully resistant pathogens. , 2004, Current opinion in microbiology.

[108]  P. Sawangwong,et al.  Drugs and Cosmetics from the Sea , 2004, Marine Drugs.

[109]  J. Hoch,et al.  Developing inhibitors to selectively target two-component and phosphorelay signal transduction systems of pathogenic microorganisms. , 2004, Current medicinal chemistry.

[110]  K. Ziegelbauer,et al.  New Class of Bacterial Phenylalanyl-tRNA Synthetase Inhibitors with High Potency and Broad-Spectrum Activity , 2004, Antimicrobial Agents and Chemotherapy.

[111]  J. Pelletier,et al.  Inhibitors of protein synthesis identified by a high throughput multiplexed translation screen. , 2004, Nucleic acids research.

[112]  Christoph Freiberg,et al.  Identification of antibiotic stress-inducible promoters: a systematic approach to novel pathway-specific reporter assays for antibacterial drug discovery. , 2003, Genome research.

[113]  David J Payne,et al.  Genomic approaches to antibacterial discovery. , 2004, Methods in molecular biology.

[114]  H. Nikaido.  Molecular Basis of Bacterial Outer Membrane Permeability Revisited , 2003, Microbiology and Molecular Biology Reviews.

[115]  Eric Haugen,et al.  Comprehensive transposon mutant library of Pseudomonas aeruginosa , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[116]  J. Greene,et al.  Microbial genetics: Genetic strategies for antibacterial drug discovery , 2003, Nature Reviews Genetics.

[117]  Jeffrey E. Barrick,et al.  Riboswitches Control Fundamental Biochemical Pathways in Bacillus subtilis and Other Bacteria , 2003, Cell.

[118]  S. D. Mills.  The role of genomics in antimicrobial discovery. , 2003, The Journal of antimicrobial chemotherapy.

[119]  Harald Labischinski,et al.  Proteomic Approach to Understanding Antibiotic Action , 2003, Antimicrobial Agents and Chemotherapy.

[120]  A. Murchie,et al.  The bacterial ribosome, a promising focus for structure-based drug design. , 2002, Current opinion in pharmacology.

[121]  Martha S. Head,et al.  Discovery of a Novel and Potent Class of FabI-Directed Antibacterial Agents , 2002, Antimicrobial Agents and Chemotherapy.

[122]  J. Koehn,et al.  N-Alkyl Urea Hydroxamic Acids as a New Class of Peptide Deformylase Inhibitors with Antibacterial Activity , 2002, Antimicrobial Agents and Chemotherapy.

[123]  Jizhong Zhou,et al.  Microbial Genomics—Challenges and Opportunities: The 9th International Conference on Microbial Genomes , 2002, Journal of bacteriology.

[124]  Elliott Bennett-Guerrero,et al.  Structure and function of lipopolysaccharides. , 2002, Microbes and infection.

[125]  Jonathan A. Mills,et al.  An array of target-specific screening strains for antibacterial discovery , 2002, Nature Biotechnology.

[126]  A. K. Forrest,et al.  Nanomolar inhibitors of Staphylococcus aureus methionyl tRNA synthetase with potent antibacterial activity against gram-positive pathogens. , 2002, Journal of medicinal chemistry.

[127]  Nina Salama,et al.  Comparison of Genetic Divergence and Fitness between Two Subclones of Helicobacter pylori , 2001, Infection and Immunity.

[128]  S Falkow,et al.  Helicobacter pylori genetic diversity within the gastric niche of a single human host , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[129]  M. Page,et al.  Peptide Deformylase as an Antibacterial Drug Target: Target Validation and Resistance Development , 2001, Antimicrobial Agents and Chemotherapy.

[130]  D. Rice,et al.  Antibiotic Activity and Characterization of BB-3497, a Novel Peptide Deformylase Inhibitor , 2001, Antimicrobial Agents and Chemotherapy.

[131]  R. Kay,et al.  Eukaryotic signal transduction via histidine-aspartate phosphorelay. , 2000, Journal of cell science.

[132]  G. Vovis,et al.  Genomics and Antimicrobial Drug Discovery , 1999, Antimicrobial Agents and Chemotherapy.

[133]  Manuel Peitsch,et al.  A genome-based approach for the identification of essential bacterial genes , 1998, Nature Biotechnology.

[134]  D. Lipman,et al.  A genomic perspective on protein families. , 1997, Science.

[135]  A. Patchett,et al.  Antibacterial Agents That Inhibit Lipid A Biosynthesis , 1996, Science.

[136]  E. Koonin,et al.  A minimal gene set for cellular life derived by comparison of complete bacterial genomes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[137]  S. Kadam.  Mechanism-based screens in the discovery of chemotherapeutic antibacterials. , 1994, Biotechnology.

[138]  V. Gold.  Compendium of chemical terminology , 1987 .